![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-adgif-27965.gif)
![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-ad-w33-mob-headergif-39012.gif)
1. 1253790-58-7
2. (r)-tert-butyl (1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl)carbamate
3. Tert-butyl (r)-(1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl)carbamate
4. Tert-butyl N-[(2r)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate
5. (r)-n-benzyl-2-(tert-butoxycarbonylamino)-3-hydroxypropionamide
6. Tert-butyl ((1r)-2-(benzylamino)-1-(hydroxymethyl)-2-oxoethyl)carbamate
7. Tert-butyl [(1r)-2-(benzylamino)-1-(hydroxymethyl)-2-oxoethyl]carbamate
8. Starbld0009742
9. Unii-x3x7nb6x9e
10. X3x7nb6x9e
11. Schembl42634
12. Tert-butyl N-[(1r)-1-(benzylcarbamoyl)-2-hydroxyethyl]carbamate
13. Zinc49582111
14. Cs-16548
15. Cs-0100204
16. D76083
17. (r)-tert-butyl 1-(benzylamino)-3-hydroxy-1-oxopropan-2-ylcarbamate
18. Tert-butyl [(2r)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate
19. Tert-butyl [(r)-2-(benzylamino)-1-(hydroxymethyl)-2-oxoethyl]carbamate
20. 1,1-dimethylethyl N-((1r)-1-(hydroxymethyl)-2-oxo-2-((phenylmethyl)amino)ethyl)carbamate
21. Carbamic Acid, N-((1r)-1-(hydroxymethyl)-2-oxo-2-((phenylmethyl)amino)ethyl)-, 1,1-dimethylethyl Ester
Molecular Weight | 294.35 g/mol |
---|---|
Molecular Formula | C15H22N2O4 |
XLogP3 | 1.1 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 7 |
Exact Mass | 294.15795719 g/mol |
Monoisotopic Mass | 294.15795719 g/mol |
Topological Polar Surface Area | 87.7 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 346 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.